Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
1 other identifier
interventional
66
1 country
1
Brief Summary
The investigators seek to compare two techniques of removing pre-cancerous lesions from the colon. The investigators also will compare two solutions used during the procedure to determine if either solution allows for an improved removal of the tumors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
Started Oct 2011
Typical duration for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 29, 2011
CompletedStudy Start
First participant enrolled
October 1, 2011
CompletedFirst Posted
Study publicly available on registry
November 16, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2014
CompletedSeptember 8, 2014
September 1, 2014
1.8 years
September 29, 2011
September 5, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Efficacy of Two Devices used in EMR
To explore the efficacy of two devices used in EMR (iSnare® system versus Snaremaster) as measured by the "Sydney Resection Quotient" (SRQ). SRQ is defined as "lesion size in mm divided by the number of pieces to resect" .
1 year
Secondary Outcomes (1)
Compare the Use of Two Injectates
1 year
Study Arms (4)
iSnare with Gonak solution
EXPERIMENTALSnaremaster braided snare with Gonak solution
EXPERIMENTALiSnare with saline solution
EXPERIMENTALSnaremaster braided snare with saline solution
EXPERIMENTALInterventions
Standard of Care Procedure as described in ARM
Eligibility Criteria
You may qualify if:
- Sessile colorectal polyp
- laterally spreading lesions as defined by Paris Classification type II and \> 1 cm or greater
You may not qualify if:
- Those with ulcerated depressed lesions (Paris type III) or biopsy proven invasive carcinoma
- Inflammatory bowel disease patients
- Coagulopathy ( INR\> 1.5) that cannot be corrected
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
- US Endoscopycollaborator
Study Sites (1)
Mayo Clinic
Jacksonville, Florida, 32224, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Timothy A Woodward, M.D.
Mayo Clinic
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
September 29, 2011
First Posted
November 16, 2011
Study Start
October 1, 2011
Primary Completion
July 1, 2013
Study Completion
May 1, 2014
Last Updated
September 8, 2014
Record last verified: 2014-09